Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Periodicals
U.S. official says COVID-19 vaccine output to start by end of summer, CNBC says » 19:22
07/13/20
07/13
19:22
07/13/20
19:22
BNTX

BioNTech

$77.73 /

+7.315 (+10.39%)

, PFE

Pfizer

$35.22 /

+1.38 (+4.08%)

, INO

Inovio

$25.57 /

+2.21 (+9.46%)

, JNJ

Johnson & Johnson

$145.30 /

+2.85 (+2.00%)

, MRNA

Moderna

$71.72 /

+9.15 (+14.62%)

, SPY

SPDR S&P 500 ETF Trust

$314.80 /

-2.81 (-0.88%)

, SPX

S&P 500

$0.00 /

+ (+0.00%)

, NVAX

Novavax

$104.46 /

+10.1 (+10.70%)

, MRK

Merck

$77.38 /

+0.64 (+0.83%)

, SNY

Sanofi

$50.96 /

+0.64 (+1.27%)

, GSK

GlaxoSmithKline

$40.07 /

+0.16 (+0.40%)

A senior Trump…

A senior Trump administration official said that U.S. health officials and drugmakers anticipate starting to make potential COVID-19 vaccine doses by the end of the summer, CNBC's Berkeley Lovelace, Jr. reports. The U.S. is seeking to deliver 300M doses of a coronavirus vaccine by early 2021, and the manufacturing process is already underway even though they aren't sure which vaccine, if any, will be effective, the author says, citing a senior Trump administration official. "Exactly when the vaccine materials will be in production and manufacturing? It's probably four to six weeks away," the official said on a call with reporters, which was hosted by the Department of Health and Human Services. "But we will be actively manufacturing by the end of the summer." Publicly traded companies working on vaccines include Moderna (MRNA), Johnson & Johnson (JNJ), Inovio (INO), Pfizer (PFE), BioNTech (BNTX), Novavax (NVAX), Merck (MRK), Sanofi (SNY), and GlaxoSmithKline (GSK). Reference Link

ShowHide Related Items >><<
SPY SPDR S&P 500 ETF Trust
$314.80 /

-2.81 (-0.88%)

SNY Sanofi
$50.96 /

+0.64 (+1.27%)

PFE Pfizer
$35.22 /

+1.38 (+4.08%)

NVAX Novavax
$104.46 /

+10.1 (+10.70%)

MRNA Moderna
$71.72 /

+9.15 (+14.62%)

MRK Merck
$77.38 /

+0.64 (+0.83%)

JNJ Johnson & Johnson
$145.30 /

+2.85 (+2.00%)

INO Inovio
$25.57 /

+2.21 (+9.46%)

GSK GlaxoSmithKline
$40.07 /

+0.16 (+0.40%)

BNTX BioNTech
$77.73 /

+7.315 (+10.39%)

BNTX BioNTech
$77.73 /

+7.315 (+10.39%)

07/13/20 Canaccord
BioNTech price target raised to $75 from $60 at Canaccord
07/02/20 B. Riley FBR
Novavax should be bought on weakness from Pfizer data, says B. Riley FBR
07/02/20 BMO Capital
Moderna mRNA platform supported by Pfizer vaccine data, says BMO Capital
07/02/20 SVB Leerink
BioNTech price target raised to $42 from $37 at SVB Leerink
PFE Pfizer
$35.22 /

+1.38 (+4.08%)

07/08/20 Piper Sandler
Opko Health price target raised to $6 from $4 at Piper Sandler
07/08/20 Argus
Pfizer positioned for stronger revenue growth in 2021 and beyond, says Argus
07/07/20 Needham
Vaxcyte initiated with a Buy at Needham
INO Inovio
$25.57 /

+2.21 (+9.46%)

07/01/20
Fly Intel: Top five analyst downgrades
07/01/20 Maxim
Inovio downgraded to Hold from Buy at Maxim
07/01/20 Roth Capital
Roth 'unimpressed' with Inovio data, downgrades to Sell with $11 target
07/01/20 Maxim
Inovio downgraded to Hold from Buy at Maxim
JNJ Johnson & Johnson
$145.30 /

+2.85 (+2.00%)

07/13/20 Oppenheimer
Relmada Therapeutics initiated with an Outperform at Oppenheimer
07/13/20 H.C. Wainwright
Pacira price target raised to $68 from $63 at H.C. Wainwright
07/10/20 Jefferies
Pacira price target raised to $69 from $53 at Jefferies
07/06/20 Baird
Cooper Companies downgraded to Neutral, Baird see confluence of issues
MRNA Moderna
$71.72 /

+9.15 (+14.62%)

07/13/20 Brookline
Moderna initiated with a Buy at Brookline
07/13/20 Jefferies
Jefferies starts Moderna with Buy rating, $90 price target
07/08/20 Piper Sandler
Piper reiterates $100 target on Moderna after Phase II study enrolled
SPY SPDR S&P 500 ETF Trust
$314.80 /

-2.81 (-0.88%)

06/04/20 Keefe Bruyette
Mattis rebuke 'wake up call' for stock market, says Keefe Bruyette
03/11/20 Goldman Sachs
Goldman Sachs believes the S&P 500 bull market will soon end
02/27/20 Keefe Bruyette
Stock market may rally Monday on 'Biden bounce,' Keefe Bruyette says
02/24/20
Dow Jones futures decline over 800 points ahead of today's open
SPX S&P 500
$0.00 /

+ (+0.00%)

NVAX Novavax
$104.46 /

+10.1 (+10.70%)

07/08/20
Fly Intel: Top five analyst downgrades
07/08/20 Ladenburg
Novavax downgraded to Neutral from Buy at Ladenburg
07/07/20 Cantor Fitzgerald
Novavax price target raised to $148 from $88 at Cantor Fitzgerald
MRK Merck
$77.38 /

+0.64 (+0.83%)

06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
SNY Sanofi
$50.96 /

+0.64 (+1.27%)

07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
07/01/20 Roth Capital
Applied Genetic may attract Sanofi takeover interest, says Roth Capital
06/26/20 SunTrust
Translate Bio initiated with a Buy at SunTrust
GSK GlaxoSmithKline
$40.07 /

+0.16 (+0.40%)

07/13/20 UBS
UBS reiterates Buy on GSK as FDA belantamab docs are out
07/13/20 JPMorgan
Ideaya upgraded to Overweight on recent pullback at JPMorgan
06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
SPY SPDR S&P 500 ETF Trust
$314.80 /

-2.81 (-0.88%)

SNY Sanofi
$50.96 /

+0.64 (+1.27%)

PFE Pfizer
$35.22 /

+1.38 (+4.08%)

NVAX Novavax
$104.46 /

+10.1 (+10.70%)

MRNA Moderna
$71.72 /

+9.15 (+14.62%)

MRK Merck
$77.38 /

+0.64 (+0.83%)

JNJ Johnson & Johnson
$145.30 /

+2.85 (+2.00%)

INO Inovio
$25.57 /

+2.21 (+9.46%)

GSK GlaxoSmithKline
$40.07 /

+0.16 (+0.40%)

BNTX BioNTech
$77.73 /

+7.315 (+10.39%)

  • 19
    May
  • 12
    Feb
  • 06
    Feb
  • 10
    Oct
SPY SPDR S&P 500 ETF Trust
$314.80 /

-2.81 (-0.88%)

SNY Sanofi
$50.96 /

+0.64 (+1.27%)

PFE Pfizer
$35.22 /

+1.38 (+4.08%)

NVAX Novavax
$104.46 /

+10.1 (+10.70%)

MRNA Moderna
$71.72 /

+9.15 (+14.62%)

MRK Merck
$77.38 /

+0.64 (+0.83%)

JNJ Johnson & Johnson
$145.30 /

+2.85 (+2.00%)

INO Inovio
$25.57 /

+2.21 (+9.46%)

GSK GlaxoSmithKline
$40.07 /

+0.16 (+0.40%)

BNTX BioNTech
$77.73 /

+7.315 (+10.39%)

SNY Sanofi
$50.96 /

+0.64 (+1.27%)

NVAX Novavax
$104.46 /

+10.1 (+10.70%)

MRNA Moderna
$71.72 /

+9.15 (+14.62%)

MRK Merck
$77.38 /

+0.64 (+0.83%)

JNJ Johnson & Johnson
$145.30 /

+2.85 (+2.00%)

INO Inovio
$25.57 /

+2.21 (+9.46%)

GSK GlaxoSmithKline
$40.07 /

+0.16 (+0.40%)

BNTX BioNTech
$77.73 /

+7.315 (+10.39%)

SPY SPDR S&P 500 ETF Trust
$314.80 /

-2.81 (-0.88%)

SPX S&P 500
$0.00 /

+ (+0.00%)

SNY Sanofi
$50.96 /

+0.64 (+1.27%)

PFE Pfizer
$35.22 /

+1.38 (+4.08%)

NVAX Novavax
$104.46 /

+10.1 (+10.70%)

MRNA Moderna
$71.72 /

+9.15 (+14.62%)

MRK Merck
$77.38 /

+0.64 (+0.83%)

JNJ Johnson & Johnson
$145.30 /

+2.85 (+2.00%)

INO Inovio
$25.57 /

+2.21 (+9.46%)

GSK GlaxoSmithKline
$40.07 /

+0.16 (+0.40%)

BNTX BioNTech
$77.73 /

+7.315 (+10.39%)

SPY SPDR S&P 500 ETF Trust
$314.80 /

-2.81 (-0.88%)

SPX S&P 500
$0.00 /

+ (+0.00%)

Initiation
Relmada Therapeutics initiated with an Outperform at Oppenheimer » 16:13
07/13/20
07/13
16:13
07/13/20
16:13
RLMD

Relmada Therapeutics

$40.65 /

-1.43 (-3.40%)

, SAGE

Sage Therapeutics

$41.13 /

-1.76 (-4.10%)

, ACAD

Acadia

$52.48 /

-2.99 (-5.39%)

, AXSM

Axsome Therapeutics

$76.78 /

-6.24 (-7.52%)

, JNJ

Johnson & Johnson

$145.18 /

+2.73 (+1.92%)

Oppenheimer analyst Jay…

Oppenheimer analyst Jay Olson initiated coverage of Relmada Therapeutics (RLMD) with an Outperform rating and $75 price target. Lead candidate REL-1017 is the first single-agent oral NMDA-receptor antagonist for Major Depressive Disorder, said Olson, who forecasts a launch of the drug in 2023 and predicts total peak sales for REL-1017 in MDD of $3.7B. While he recognizes several competitors in the MDD space - including Sage Therapeutics (SAGE), Acadia (ACAD), Axsome Therapeutics (AXSM) and Johnson & Johnson (JNJ) - Olson sees a sufficiently large market for multiple players and sees several "distinct advantages" for REL-1017, he tells investors.

ShowHide Related Items >><<
SAGE Sage Therapeutics
$41.13 /

-1.76 (-4.10%)

RLMD Relmada Therapeutics
$40.65 /

-1.43 (-3.40%)

JNJ Johnson & Johnson
$145.18 /

+2.73 (+1.92%)

AXSM Axsome Therapeutics
$76.78 /

-6.24 (-7.52%)

ACAD Acadia
$52.48 /

-2.99 (-5.39%)

RLMD Relmada Therapeutics
$40.65 /

-1.43 (-3.40%)

05/27/20 Goldman Sachs
Goldman says Relmada clearance for Phase 3 supports REL-1017 safety, efficacy
05/04/20 SunTrust
Relmada Therapeutics initiated with a Buy at SunTrust
05/04/20
Fly Intel: Top five analyst initiations
04/21/20 Goldman Sachs
Relmada Therapeutics initiated with a Buy at Goldman Sachs
SAGE Sage Therapeutics
$41.13 /

-1.76 (-4.10%)

05/26/20 RBC Capital
Sage Therapeutics price target raised to $75 from $72 at RBC Capital
05/08/20 Wedbush
Sage Therapeutics downgraded at Wedbush on lack of catalysts
05/08/20 Wedbush
Sage Therapeutics downgraded to Neutral from Outperform at Wedbush
05/08/20 Mizuho
Sage Therapeutics price target raised to $44 from $36 at Mizuho
ACAD Acadia
$52.48 /

-2.99 (-5.39%)

07/09/20 RBC Capital
Acadia price target raised to $61 from $58 at RBC Capital
07/07/20
Fly Intel: Top five analyst upgrades
07/06/20 Stifel
Acadia upgraded to Buy from Hold at Stifel
06/24/20 Citi
Acadia risk/reward skewed to upside into depression data, says Citi
AXSM Axsome Therapeutics
$76.78 /

-6.24 (-7.52%)

04/28/20 Guggenheim
Axsome Therapeutics price target raised to $200 from $158 at Guggenheim
04/28/20 SunTrust
Axsome Therapeutics price target raised to $200 from $145 at SunTrust
04/28/20 Cantor Fitzgerald
Axsome Therapeutics price target raised to $131 from $125 at Cantor Fitzgerald
04/28/20 H.C. Wainwright
Axsome Therapeutics price target raised to $210 from $200 at H.C. Wainwright
JNJ Johnson & Johnson
$145.18 /

+2.73 (+1.92%)

07/13/20 H.C. Wainwright
Pacira price target raised to $68 from $63 at H.C. Wainwright
07/10/20 Jefferies
Pacira price target raised to $69 from $53 at Jefferies
07/06/20 Baird
Cooper Companies downgraded to Neutral, Baird see confluence of issues
07/01/20 JMP Securities
Minerva's seltorexant still 'underappreciated' upside driver, says JMP
SAGE Sage Therapeutics
$41.13 /

-1.76 (-4.10%)

JNJ Johnson & Johnson
$145.18 /

+2.73 (+1.92%)

AXSM Axsome Therapeutics
$76.78 /

-6.24 (-7.52%)

ACAD Acadia
$52.48 /

-2.99 (-5.39%)

  • 19
    Dec
  • 04
    Dec
  • 18
    Sep
JNJ Johnson & Johnson
$145.18 /

+2.73 (+1.92%)

JNJ Johnson & Johnson
$145.18 /

+2.73 (+1.92%)

AXSM Axsome Therapeutics
$76.78 /

-6.24 (-7.52%)

ACAD Acadia
$52.48 /

-2.99 (-5.39%)

JNJ Johnson & Johnson
$145.18 /

+2.73 (+1.92%)

AXSM Axsome Therapeutics
$76.78 /

-6.24 (-7.52%)

Recommendations
Pacira price target raised to $68 from $63 at H.C. Wainwright » 08:42
07/13/20
07/13
08:42
07/13/20
08:42
PCRX

Pacira

$57.84 /

+0.19 (+0.33%)

, JNJ

Johnson & Johnson

$142.45 /

-0.01 (-0.01%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Oren Livnat raised the firm's price target on Pacira Pharmaceuticals (PCRX) to $68 from $63 and reiterates a Buy rating on the shares. Heron Therapeutics' (HRTX) recent Complete Response Letter, Pacira choosing to terminate the co-promotion agreement with Johnson & Johnson (JNJ) at the beginning of 2021 and its better than expected preannounced Q2 revenue are increment positives, Livnat tells investors in a research note.

ShowHide Related Items >><<
PCRX Pacira
$57.84 /

+0.19 (+0.33%)

JNJ Johnson & Johnson
$142.45 /

-0.01 (-0.01%)

PCRX Pacira
$57.84 /

+0.19 (+0.33%)

07/10/20 Jefferies
Pacira price target raised to $69 from $53 at Jefferies
07/06/20 Needham
Pacira price target raised to $64 from $52 at Needham
07/06/20 Piper Sandler
Pacira price target raised to $65 from $49 at Piper Sandler
07/01/20 RBC Capital
Pacira price target raised to $62 from $56 at RBC Capital
JNJ Johnson & Johnson
$142.45 /

-0.01 (-0.01%)

07/06/20 Baird
Cooper Companies downgraded to Neutral, Baird see confluence of issues
07/01/20 JMP Securities
Minerva's seltorexant still 'underappreciated' upside driver, says JMP
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
PCRX Pacira
$57.84 /

+0.19 (+0.33%)

JNJ Johnson & Johnson
$142.45 /

-0.01 (-0.01%)

JNJ Johnson & Johnson
$142.45 /

-0.01 (-0.01%)

PCRX Pacira
$57.84 /

+0.19 (+0.33%)

JNJ Johnson & Johnson
$142.45 /

-0.01 (-0.01%)

JNJ Johnson & Johnson
$142.45 /

-0.01 (-0.01%)

Friday
Recommendations
Pacira price target raised to $69 from $53 at Jefferies » 07:41
07/10/20
07/10
07:41
07/10/20
07:41
PCRX

Pacira

$57.65 /

+1.11 (+1.96%)

, JNJ

Johnson & Johnson

$142.46 /

-0.78 (-0.54%)

Jefferies analyst David…

Jefferies analyst David Steinberg raised the firm's price target on Pacira (PCRX) to $69 from $53 and keeps a Buy rating on the shares after the company pre-announced "surprisingly strong" June sales. He also sees the company's decision to terminate the "largely redundant" Exparel copromotion agreement with Johnson & Johnson (JNJ) yielding "very meaningful" cost savings and enhanced profitability starting next year, Steinberg tells investors.

ShowHide Related Items >><<
PCRX Pacira
$57.65 /

+1.11 (+1.96%)

JNJ Johnson & Johnson
$142.46 /

-0.78 (-0.54%)

PCRX Pacira
$57.65 /

+1.11 (+1.96%)

07/06/20 Needham
Pacira price target raised to $64 from $52 at Needham
07/06/20 Piper Sandler
Pacira price target raised to $65 from $49 at Piper Sandler
07/01/20 RBC Capital
Pacira price target raised to $62 from $56 at RBC Capital
06/30/20 SVB Leerink
Pacira price target raised to $58 from $45 at SVB Leerink
JNJ Johnson & Johnson
$142.46 /

-0.78 (-0.54%)

07/06/20 Baird
Cooper Companies downgraded to Neutral, Baird see confluence of issues
07/01/20 JMP Securities
Minerva's seltorexant still 'underappreciated' upside driver, says JMP
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
05/29/20 H.C. Wainwright
H.C. Wainwright sees path forward for Minerva's roluperidone despite setback
PCRX Pacira
$57.65 /

+1.11 (+1.96%)

JNJ Johnson & Johnson
$142.46 /

-0.78 (-0.54%)

JNJ Johnson & Johnson
$142.46 /

-0.78 (-0.54%)

PCRX Pacira
$57.65 /

+1.11 (+1.96%)

JNJ Johnson & Johnson
$142.46 /

-0.78 (-0.54%)

JNJ Johnson & Johnson
$142.46 /

-0.78 (-0.54%)

Thursday
Hot Stocks
Pfizer pledges $100M to new Antimicrobial Resistance Action Fund » 15:23
07/09/20
07/09
15:23
07/09/20
15:23
PFE

Pfizer

$33.57 /

-0.19 (-0.56%)

, AMGN

Amgen

$252.34 /

+0.74 (+0.29%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, LLY

Eli Lilly

$166.59 /

-2.52 (-1.49%)

, GSK

GlaxoSmithKline

$40.37 /

-0.35 (-0.86%)

, MRK

Merck

$76.99 /

-0.88 (-1.13%)

, MKGAY

Merck KGaA

$0.00 /

+ (+0.00%)

, TEVA

Teva

$11.60 /

+0.21 (+1.84%)

, TAK

Takeda Pharmaceutical

$17.36 /

-0.135 (-0.77%)

, NVO

Novo Nordisk

$65.63 /

-0.23 (-0.35%)

, JNJ

Johnson & Johnson

$143.03 /

-0.21 (-0.15%)

, NVS

Novartis

$87.53 /

-0.585 (-0.66%)

Pfizer (PFE) announced…

Pfizer (PFE) announced earlier it has pledged $100M to the new Antimicrobial Resistance, or "AMR," Action Fund, which launched today, to help address the significant global public health need for new antibiotics due to the rapid rise of antibiotic-resistant infections. "The AMR Action Fund is a ground-breaking collaboration among more than 20 biopharmaceutical companies that aims to bring 2-4 new antibiotics to patients by 2030 through collaboration between pharmaceutical companies, philanthropies, development banks, and multilateral organizations to re-invigorate and accelerate antibiotic development," the company stated. "As the COVID-19 pandemic has shown, we must invest in the development of medicines now so that we are prepared to help prevent the next public health crisis," added Pfizer Chairman and CEO Albert Bourla. Other investors in the AMR Action Fund include Amgen (AMGN), Bayer (BAYRY), Roche (RHHBY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Merck (MRK), Merck KGaA (MKGAY), Teva (TEVA), Takeda Pharmaceutical (TAK), Novo Nordisk (NVO), Johnson & Johnson (JNJ) and Novartis (NVS). Reference Link

ShowHide Related Items >><<
TEVA Teva
$11.60 /

+0.21 (+1.84%)

TAK Takeda Pharmaceutical
$17.36 /

-0.135 (-0.77%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

NVS Novartis
$87.53 /

-0.585 (-0.66%)

NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

MKGAY Merck KGaA
$0.00 /

+ (+0.00%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

07/08/20 Piper Sandler
Opko Health price target raised to $6 from $4 at Piper Sandler
07/08/20 Argus
Pfizer positioned for stronger revenue growth in 2021 and beyond, says Argus
07/07/20 Needham
Vaxcyte initiated with a Buy at Needham
07/02/20 B. Riley FBR
Novavax should be bought on weakness from Pfizer data, says B. Riley FBR
AMGN Amgen
$252.34 /

+0.74 (+0.29%)

07/02/20 Citi
Citi sees 'considerable amount of investor interest' coming back to Amgen
07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Mizuho
Amgen patent win worth $5-$12 per share, says Mizuho
07/01/20 Goldman Sachs
Court ruling removes overhang for Amgen, says Goldman Sachs
BAYRY Bayer
$0.00 /

+ (+0.00%)

06/26/20 JPMorgan
Bayer price target raised to EUR 77 from EUR 75 at JPMorgan
06/26/20 Deutsche Bank
Bayer price target raised to EUR 87 from EUR 85 at Deutsche Bank
06/25/20 Morgan Stanley
Bayer price target raised to EUR 88 from EUR 83 at Morgan Stanley
06/25/20 HSBC
HSBC upgrades Bayer to Buy after settlement on most Monsanto cases in U.S.
RHHBY Roche
$0.00 /

+ (+0.00%)

07/03/20 AlphaValue
Roche upgraded to Add from Reduce at AlphaValue
06/29/20 Piper Sandler
Herceptin/Perjecta approval another win for Halozyme, says Piper
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

07/09/20 Morgan Stanley
Eli Lilly won't publish Phase 1 COVID antibody data, says Morgan Stanley
06/29/20 Mizuho
Eli Lilly price target raised to $164 from $155 at Mizuho
06/17/20 JPMorgan
Eli Lilly price target raised to $190 from $175 at JPMorgan
GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
MRK Merck
$76.99 /

-0.88 (-1.13%)

06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
MKGAY Merck KGaA
$0.00 /

+ (+0.00%)

05/15/20 Nord/LB
Merck KGaA downgraded to Hold from Buy at Nord/LB
03/06/20 UBS
UBS backs Neutral on Merck KGaA after Q4 results
12/02/19 Goldman Sachs
Merck KGaA reinstated with a Sell at Goldman Sachs
10/04/19 Loop Capital
Entegris price target raised to $51 from $47 at Loop Capital
TEVA Teva
$11.60 /

+0.21 (+1.84%)

07/02/20 Wells Fargo
Emergent BioSolutions price target raised to $93 from $85 at Wells Fargo
06/26/20 William Blair
Pfenex partner CHMP opinion 'material de-risking event,' says William Blair
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
06/08/20 Guggenheim
Emergent BioSolutions price target lowered to $87 from $101 at Guggenheim
TAK Takeda Pharmaceutical
$17.36 /

-0.135 (-0.77%)

06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

07/06/20 BofA
Novo Nordisk downgraded to Neutral from Buy at BofA
06/05/20 JPMorgan
JPMorgan backs Overweight on Novo Nordisk after STEP data
05/18/20 Morgan Stanley
Novo Nordisk price target raised to DKK 435 from DKK 425 at Morgan Stanley
05/13/20 JPMorgan
Novo Nordisk price target raised to DKK 480 from DKK 460 at JPMorgan
JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

07/06/20 Baird
Cooper Companies downgraded to Neutral, Baird see confluence of issues
07/01/20 JMP Securities
Minerva's seltorexant still 'underappreciated' upside driver, says JMP
05/29/20 H.C. Wainwright
H.C. Wainwright sees path forward for Minerva's roluperidone despite setback
NVS Novartis
$87.53 /

-0.585 (-0.66%)

07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
TEVA Teva
$11.60 /

+0.21 (+1.84%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

NVS Novartis
$87.53 /

-0.585 (-0.66%)

NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

TEVA Teva
$11.60 /

+0.21 (+1.84%)

TAK Takeda Pharmaceutical
$17.36 /

-0.135 (-0.77%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

MKGAY Merck KGaA
$0.00 /

+ (+0.00%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

TEVA Teva
$11.60 /

+0.21 (+1.84%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

NVS Novartis
$87.53 /

-0.585 (-0.66%)

NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

TEVA Teva
$11.60 /

+0.21 (+1.84%)

TAK Takeda Pharmaceutical
$17.36 /

-0.135 (-0.77%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

NVS Novartis
$87.53 /

-0.585 (-0.66%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

Conference/Events
Oxford Global Marketing to hold a virtual event » 04:55
07/09/20
07/09
04:55
07/09/20
04:55
ABBV

AbbVie

$99.28 /

-0.06 (-0.06%)

, AZN

AstraZeneca

$54.19 /

+0.7 (+1.31%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BMY

Bristol-Myers

$59.58 /

-0.72 (-1.19%)

, GSK

GlaxoSmithKline

$40.72 /

+0.34 (+0.84%)

, IPSEY

Ipsen

$0.00 /

+ (+0.00%)

, JAZZ

Jazz Pharmaceuticals

$107.54 /

-1.18 (-1.09%)

, JNJ

Johnson & Johnson

$143.24 /

+0.43 (+0.30%)

, NVS

Novartis

$88.12 /

+0.345 (+0.39%)

, PFE

Pfizer

$33.76 /

-0.27 (-0.79%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, RTRX

Retrophin

$20.86 /

-0.04 (-0.19%)

, SNY

Sanofi

$51.54 /

+0.14 (+0.27%)

, TAK

Takeda Pharmaceutical

$17.49 /

+0.01 (+0.06%)

, TEVA

Teva

$11.39 /

+0.17 (+1.52%)

Formulation &…

Formulation & Delivery Series Biomanufacturing Virtual Congress will be held on July 8-9. Webcast Link

ShowHide Related Items >><<
TEVA Teva
$11.39 /

+0.17 (+1.52%)

TAK Takeda Pharmaceutical
$17.49 /

+0.01 (+0.06%)

SNY Sanofi
$51.54 /

+0.14 (+0.27%)

RTRX Retrophin
$20.86 /

-0.04 (-0.19%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.76 /

-0.27 (-0.79%)

NVS Novartis
$88.12 /

+0.345 (+0.39%)

JNJ Johnson & Johnson
$143.24 /

+0.43 (+0.30%)

JAZZ Jazz Pharmaceuticals
$107.54 /

-1.18 (-1.09%)

IPSEY Ipsen
$0.00 /

+ (+0.00%)

GSK GlaxoSmithKline
$40.72 /

+0.34 (+0.84%)

BMY Bristol-Myers
$59.58 /

-0.72 (-1.19%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.19 /

+0.7 (+1.31%)

ABBV AbbVie
$99.28 /

-0.06 (-0.06%)

ABBV AbbVie
$99.28 /

-0.06 (-0.06%)

07/07/20 SunTrust
Evolus price target lowered to $6 from $12 at SunTrust
07/06/20 Piper Sandler
Biohaven launch of Nurtec 'continues to impress,' says Piper Sandler
06/29/20 Mizuho
AbbVie price target raised to $110 from $101 at Mizuho
06/26/20 Raymond James
Adverum Biotechnologies downgradedat Raymond James on abicipar CRL
AZN AstraZeneca
$54.19 /

+0.7 (+1.31%)

06/24/20 Oddo BHF
AstraZeneca downgraded to Reduce from Buy at Oddo BHF
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/10/20 Cowen
AstraZeneca price target raised to $60 from $55 at Cowen
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
BAYRY Bayer
$0.00 /

+ (+0.00%)

06/26/20 JPMorgan
Bayer price target raised to EUR 77 from EUR 75 at JPMorgan
06/26/20 Deutsche Bank
Bayer price target raised to EUR 87 from EUR 85 at Deutsche Bank
06/25/20 Morgan Stanley
Bayer price target raised to EUR 88 from EUR 83 at Morgan Stanley
06/25/20 HSBC
HSBC upgrades Bayer to Buy after settlement on most Monsanto cases in U.S.
BMY Bristol-Myers
$59.58 /

-0.72 (-1.19%)

06/22/20 Morgan Stanley
Morgan Stanley sees Eliquis patent being upheld, ruling being 'imminent'
06/08/20 Bernstein
Gilead, AstraZeneca merger would make sense on economic basis, says Bernstein
06/02/20 Credit Suisse
Arena Pharmaceuticals price target raised to $87 from $77 at Credit Suisse
06/02/20 Cantor Fitzgerald
Arena Pharmaceuticals price target raised to $88 from $68 at Cantor Fitzgerald
GSK GlaxoSmithKline
$40.72 /

+0.34 (+0.84%)

06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
IPSEY Ipsen
$0.00 /

+ (+0.00%)

06/08/20 Bryan Garnier
Ipsen upgraded to Buy from Neutral at Bryan Garnier
06/01/20 Barclays
Ipsen price target raised to EUR 72 from EUR 62 at Barclays
06/01/20 BofA
Ipsen upgraded to Buy from Neutral at BofA
05/18/20 JPMorgan
Ipsen upgraded to Neutral on Cabometyx potential at JPMorgan
JAZZ Jazz Pharmaceuticals
$107.54 /

-1.18 (-1.09%)

06/23/20 Barclays
Jazz Pharmaceuticals price target raised to $195 from $183 at Barclays
06/01/20 SVB Leerink
Jazz Pharmaceuticals price target raised to $169 from $160 at SVB Leerink
05/06/20 SVB Leerink
Jazz Pharmaceuticals price target lowered to $160 from $169 at SVB Leerink
05/06/20 Oppenheimer
Jazz Pharmaceuticals price target lowered to $132 from $141 at Oppenheimer
JNJ Johnson & Johnson
$143.24 /

+0.43 (+0.30%)

07/06/20 Baird
Cooper Companies downgraded to Neutral, Baird see confluence of issues
07/01/20 JMP Securities
Minerva's seltorexant still 'underappreciated' upside driver, says JMP
05/29/20 H.C. Wainwright
H.C. Wainwright sees path forward for Minerva's roluperidone despite setback
NVS Novartis
$88.12 /

+0.345 (+0.39%)

07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
PFE Pfizer
$33.76 /

-0.27 (-0.79%)

07/08/20 Piper Sandler
Opko Health price target raised to $6 from $4 at Piper Sandler
07/08/20 Argus
Pfizer positioned for stronger revenue growth in 2021 and beyond, says Argus
07/07/20 Needham
Vaxcyte initiated with a Buy at Needham
07/02/20 B. Riley FBR
Novavax should be bought on weakness from Pfizer data, says B. Riley FBR
RHHBY Roche
$0.00 /

+ (+0.00%)

07/03/20 AlphaValue
Roche upgraded to Add from Reduce at AlphaValue
06/29/20 Piper Sandler
Herceptin/Perjecta approval another win for Halozyme, says Piper
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
RTRX Retrophin
$20.86 /

-0.04 (-0.19%)

06/16/20 BTIG
Retrophin initiated with a Buy at BTIG
02/25/20 Barclays
Retrophin downgraded to Equal Weight from Overweight at Barclays
01/13/20 JMP Securities
JMP says continues to like Retrophin opportunity
08/23/19 BMO Capital
Retrophin price target lowered to $33 from $38 at BMO Capital
SNY Sanofi
$51.54 /

+0.14 (+0.27%)

07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
07/01/20 Roth Capital
Applied Genetic may attract Sanofi takeover interest, says Roth Capital
06/26/20 SunTrust
Translate Bio initiated with a Buy at SunTrust
TAK Takeda Pharmaceutical
$17.49 /

+0.01 (+0.06%)

06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
TEVA Teva
$11.39 /

+0.17 (+1.52%)

07/02/20 Wells Fargo
Emergent BioSolutions price target raised to $93 from $85 at Wells Fargo
06/26/20 William Blair
Pfenex partner CHMP opinion 'material de-risking event,' says William Blair
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
06/08/20 Guggenheim
Emergent BioSolutions price target lowered to $87 from $101 at Guggenheim
TEVA Teva
$11.39 /

+0.17 (+1.52%)

SNY Sanofi
$51.54 /

+0.14 (+0.27%)

RTRX Retrophin
$20.86 /

-0.04 (-0.19%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.76 /

-0.27 (-0.79%)

NVS Novartis
$88.12 /

+0.345 (+0.39%)

JNJ Johnson & Johnson
$143.24 /

+0.43 (+0.30%)

JAZZ Jazz Pharmaceuticals
$107.54 /

-1.18 (-1.09%)

GSK GlaxoSmithKline
$40.72 /

+0.34 (+0.84%)

BMY Bristol-Myers
$59.58 /

-0.72 (-1.19%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.19 /

+0.7 (+1.31%)

ABBV AbbVie
$99.28 /

-0.06 (-0.06%)

  • 09
    Jun
TEVA Teva
$11.39 /

+0.17 (+1.52%)

TAK Takeda Pharmaceutical
$17.49 /

+0.01 (+0.06%)

SNY Sanofi
$51.54 /

+0.14 (+0.27%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.76 /

-0.27 (-0.79%)

NVS Novartis
$88.12 /

+0.345 (+0.39%)

JNJ Johnson & Johnson
$143.24 /

+0.43 (+0.30%)

GSK GlaxoSmithKline
$40.72 /

+0.34 (+0.84%)

BMY Bristol-Myers
$59.58 /

-0.72 (-1.19%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.19 /

+0.7 (+1.31%)

ABBV AbbVie
$99.28 /

-0.06 (-0.06%)

TEVA Teva
$11.39 /

+0.17 (+1.52%)

SNY Sanofi
$51.54 /

+0.14 (+0.27%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.76 /

-0.27 (-0.79%)

NVS Novartis
$88.12 /

+0.345 (+0.39%)

JNJ Johnson & Johnson
$143.24 /

+0.43 (+0.30%)

JAZZ Jazz Pharmaceuticals
$107.54 /

-1.18 (-1.09%)

IPSEY Ipsen
$0.00 /

+ (+0.00%)

GSK GlaxoSmithKline
$40.72 /

+0.34 (+0.84%)

BMY Bristol-Myers
$59.58 /

-0.72 (-1.19%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.19 /

+0.7 (+1.31%)

ABBV AbbVie
$99.28 /

-0.06 (-0.06%)

TEVA Teva
$11.39 /

+0.17 (+1.52%)

TAK Takeda Pharmaceutical
$17.49 /

+0.01 (+0.06%)

SNY Sanofi
$51.54 /

+0.14 (+0.27%)

PFE Pfizer
$33.76 /

-0.27 (-0.79%)

NVS Novartis
$88.12 /

+0.345 (+0.39%)

JNJ Johnson & Johnson
$143.24 /

+0.43 (+0.30%)

GSK GlaxoSmithKline
$40.72 /

+0.34 (+0.84%)

BMY Bristol-Myers
$59.58 /

-0.72 (-1.19%)

AZN AstraZeneca
$54.19 /

+0.7 (+1.31%)

ABBV AbbVie
$99.28 /

-0.06 (-0.06%)

Wednesday
Periodicals
J&J's Cilag to offer up to 11.8M Idorsia ordinary shares, Reuters says » 12:18
07/08/20
07/08
12:18
07/08/20
12:18
JNJ

Johnson & Johnson

$142.24 /

-0.57 (-0.40%)

, IDRSF

Idorsia

$0.00 /

+ (+0.00%)

, GS

Goldman Sachs

$200.28 /

+1.02 (+0.51%)

Johnson &…

Johnson & Johnson's (JNJ) Cilag Holding intends to offer up to roughly 11.8M existing ordinary shares in Idorsia (IDRSF) in an accelerated bookbuilding to begin on Wednesday, Reuters' Brenna Hughes Neghaiwi reports, citing the transaction's bookrunner. The sale corresponds to about 8.3% of Idorsia's outstanding ordinary share capital, the author says, noting that Goldman Sachs (GS) will serve as sole bookrunner. Reference Link

ShowHide Related Items >><<
JNJ Johnson & Johnson
$142.24 /

-0.57 (-0.40%)

GS Goldman Sachs
$200.28 /

+1.02 (+0.51%)

JNJ Johnson & Johnson
$142.24 /

-0.57 (-0.40%)

07/06/20 Baird
Cooper Companies downgraded to Neutral, Baird see confluence of issues
07/01/20 JMP Securities
Minerva's seltorexant still 'underappreciated' upside driver, says JMP
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
05/29/20 H.C. Wainwright
H.C. Wainwright sees path forward for Minerva's roluperidone despite setback
IDRSF Idorsia
$0.00 /

+ (+0.00%)

07/08/20 JPMorgan
Idorsia initiated with a Neutral at JPMorgan
06/15/20 Deutsche Bank
Idorsia initiated with a Buy at Deutsche Bank
05/11/20 Credit Suisse
Idorsia upgraded to Outperform from Neutral at Credit Suisse
04/20/20 H.C. Wainwright
Idorsia price target raised to CHF 45 from CHF 38 at H.C. Wainwright
GS Goldman Sachs
$200.28 /

+1.02 (+0.51%)

07/08/20 Seaport Global
Goldman Sachs initiated with a Buy at Seaport Global
06/26/20 Morgan Stanley
Morgan Stanley sees dividend cuts at Wells Fargo, Capital One after stress tests
06/05/20 Wells Fargo
Goldman Sachs price target raised to $255 from $230 at Wells Fargo
06/04/20
Fly Intel: Top five analyst downgrades
JNJ Johnson & Johnson
$142.24 /

-0.57 (-0.40%)

GS Goldman Sachs
$200.28 /

+1.02 (+0.51%)

JNJ Johnson & Johnson
$142.24 /

-0.57 (-0.40%)

GS Goldman Sachs
$200.28 /

+1.02 (+0.51%)

JNJ Johnson & Johnson
$142.24 /

-0.57 (-0.40%)

GS Goldman Sachs
$200.28 /

+1.02 (+0.51%)

JNJ Johnson & Johnson
$142.24 /

-0.57 (-0.40%)

GS Goldman Sachs
$200.28 /

+1.02 (+0.51%)

Conference/Events
Oxford Global Marketing to hold a virtual event » 09:24
07/08/20
07/08
09:24
07/08/20
09:24
ABBV

AbbVie

$99.34 /

+0.31 (+0.31%)

, AZN

AstraZeneca

$53.49 /

-0.61 (-1.13%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BMY

Bristol-Myers

$60.30 /

+0.09 (+0.15%)

, GSK

GlaxoSmithKline

$40.38 /

-0.625 (-1.52%)

, IPSEY

Ipsen

$0.00 /

+ (+0.00%)

, JAZZ

Jazz Pharmaceuticals

$108.72 /

-2.48 (-2.23%)

, JNJ

Johnson & Johnson

$142.81 /

-0.18 (-0.13%)

, NVS

Novartis

$87.77 /

-0.65 (-0.74%)

, PFE

Pfizer

$34.03 /

-0.48 (-1.39%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, RTRX

Retrophin

$20.90 /

+0.34 (+1.65%)

, SNY

Sanofi

$51.40 /

-0.78 (-1.49%)

, TAK

Takeda Pharmaceutical

$17.48 /

-0.18 (-1.02%)

, TEVA

Teva

$11.22 /

-0.31 (-2.69%)

Formulation &…

Formulation & Delivery Series Biomanufacturing Virtual Congress will be held on July 8-9. Webcast Link

ShowHide Related Items >><<
TEVA Teva
$11.22 /

-0.31 (-2.69%)

TAK Takeda Pharmaceutical
$17.48 /

-0.18 (-1.02%)

SNY Sanofi
$51.40 /

-0.78 (-1.49%)

RTRX Retrophin
$20.90 /

+0.34 (+1.65%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$34.03 /

-0.48 (-1.39%)

NVS Novartis
$87.77 /

-0.65 (-0.74%)

JNJ Johnson & Johnson
$142.81 /

-0.18 (-0.13%)

JAZZ Jazz Pharmaceuticals
$108.72 /

-2.48 (-2.23%)

IPSEY Ipsen
$0.00 /

+ (+0.00%)

GSK GlaxoSmithKline
$40.38 /

-0.625 (-1.52%)

BMY Bristol-Myers
$60.30 /

+0.09 (+0.15%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.49 /

-0.61 (-1.13%)

ABBV AbbVie
$99.34 /

+0.31 (+0.31%)

ABBV AbbVie
$99.34 /

+0.31 (+0.31%)

07/07/20 SunTrust
Evolus price target lowered to $6 from $12 at SunTrust
07/06/20 Piper Sandler
Biohaven launch of Nurtec 'continues to impress,' says Piper Sandler
06/29/20 Mizuho
AbbVie price target raised to $110 from $101 at Mizuho
06/26/20 Raymond James
Adverum Biotechnologies downgradedat Raymond James on abicipar CRL
AZN AstraZeneca
$53.49 /

-0.61 (-1.13%)

06/24/20 Oddo BHF
AstraZeneca downgraded to Reduce from Buy at Oddo BHF
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/10/20 Cowen
AstraZeneca price target raised to $60 from $55 at Cowen
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
BAYRY Bayer
$0.00 /

+ (+0.00%)

06/26/20 JPMorgan
Bayer price target raised to EUR 77 from EUR 75 at JPMorgan
06/26/20 Deutsche Bank
Bayer price target raised to EUR 87 from EUR 85 at Deutsche Bank
06/25/20 Morgan Stanley
Bayer price target raised to EUR 88 from EUR 83 at Morgan Stanley
06/25/20 HSBC
HSBC upgrades Bayer to Buy after settlement on most Monsanto cases in U.S.
BMY Bristol-Myers
$60.30 /

+0.09 (+0.15%)

06/22/20 Morgan Stanley
Morgan Stanley sees Eliquis patent being upheld, ruling being 'imminent'
06/08/20 Bernstein
Gilead, AstraZeneca merger would make sense on economic basis, says Bernstein
06/02/20 Credit Suisse
Arena Pharmaceuticals price target raised to $87 from $77 at Credit Suisse
06/02/20 Cantor Fitzgerald
Arena Pharmaceuticals price target raised to $88 from $68 at Cantor Fitzgerald
GSK GlaxoSmithKline
$40.38 /

-0.625 (-1.52%)

06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
IPSEY Ipsen
$0.00 /

+ (+0.00%)

06/08/20 Bryan Garnier
Ipsen upgraded to Buy from Neutral at Bryan Garnier
06/01/20 Barclays
Ipsen price target raised to EUR 72 from EUR 62 at Barclays
06/01/20 BofA
Ipsen upgraded to Buy from Neutral at BofA
05/18/20 JPMorgan
Ipsen upgraded to Neutral on Cabometyx potential at JPMorgan
JAZZ Jazz Pharmaceuticals
$108.72 /

-2.48 (-2.23%)

06/23/20 Barclays
Jazz Pharmaceuticals price target raised to $195 from $183 at Barclays
06/01/20 SVB Leerink
Jazz Pharmaceuticals price target raised to $169 from $160 at SVB Leerink
05/06/20 SVB Leerink
Jazz Pharmaceuticals price target lowered to $160 from $169 at SVB Leerink
05/06/20 Oppenheimer
Jazz Pharmaceuticals price target lowered to $132 from $141 at Oppenheimer
JNJ Johnson & Johnson
$142.81 /

-0.18 (-0.13%)

07/06/20 Baird
Cooper Companies downgraded to Neutral, Baird see confluence of issues
07/01/20 JMP Securities
Minerva's seltorexant still 'underappreciated' upside driver, says JMP
05/29/20 H.C. Wainwright
H.C. Wainwright sees path forward for Minerva's roluperidone despite setback
NVS Novartis
$87.77 /

-0.65 (-0.74%)

07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
PFE Pfizer
$34.03 /

-0.48 (-1.39%)

07/08/20 Argus
Pfizer positioned for stronger revenue growth in 2021 and beyond, says Argus
07/07/20 Needham
Vaxcyte initiated with a Buy at Needham
07/02/20 B. Riley FBR
Novavax should be bought on weakness from Pfizer data, says B. Riley FBR
07/02/20 BMO Capital
Moderna mRNA platform supported by Pfizer vaccine data, says BMO Capital
RHHBY Roche
$0.00 /

+ (+0.00%)

07/03/20 AlphaValue
Roche upgraded to Add from Reduce at AlphaValue
06/29/20 Piper Sandler
Herceptin/Perjecta approval another win for Halozyme, says Piper
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
RTRX Retrophin
$20.90 /

+0.34 (+1.65%)

06/16/20 BTIG
Retrophin initiated with a Buy at BTIG
02/25/20 Barclays
Retrophin downgraded to Equal Weight from Overweight at Barclays
01/13/20 JMP Securities
JMP says continues to like Retrophin opportunity
08/23/19 BMO Capital
Retrophin price target lowered to $33 from $38 at BMO Capital
SNY Sanofi
$51.40 /

-0.78 (-1.49%)

07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
07/01/20 Roth Capital
Applied Genetic may attract Sanofi takeover interest, says Roth Capital
06/26/20 SunTrust
Translate Bio initiated with a Buy at SunTrust
06/24/20 Roth Capital
Translate Bio price target raised to $30 from $25 at Roth Capital
TAK Takeda Pharmaceutical
$17.48 /

-0.18 (-1.02%)

06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
TEVA Teva
$11.22 /

-0.31 (-2.69%)

07/02/20 Wells Fargo
Emergent BioSolutions price target raised to $93 from $85 at Wells Fargo
06/26/20 William Blair
Pfenex partner CHMP opinion 'material de-risking event,' says William Blair
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
06/08/20 Guggenheim
Emergent BioSolutions price target lowered to $87 from $101 at Guggenheim
TEVA Teva
$11.22 /

-0.31 (-2.69%)

SNY Sanofi
$51.40 /

-0.78 (-1.49%)

RTRX Retrophin
$20.90 /

+0.34 (+1.65%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$34.03 /

-0.48 (-1.39%)

NVS Novartis
$87.77 /

-0.65 (-0.74%)

JNJ Johnson & Johnson
$142.81 /

-0.18 (-0.13%)

JAZZ Jazz Pharmaceuticals
$108.72 /

-2.48 (-2.23%)

GSK GlaxoSmithKline
$40.38 /

-0.625 (-1.52%)

BMY Bristol-Myers
$60.30 /

+0.09 (+0.15%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.49 /

-0.61 (-1.13%)

ABBV AbbVie
$99.34 /

+0.31 (+0.31%)

  • 09
    Jun
TEVA Teva
$11.22 /

-0.31 (-2.69%)

TAK Takeda Pharmaceutical
$17.48 /

-0.18 (-1.02%)

SNY Sanofi
$51.40 /

-0.78 (-1.49%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$34.03 /

-0.48 (-1.39%)

NVS Novartis
$87.77 /

-0.65 (-0.74%)

JNJ Johnson & Johnson
$142.81 /

-0.18 (-0.13%)

GSK GlaxoSmithKline
$40.38 /

-0.625 (-1.52%)

BMY Bristol-Myers
$60.30 /

+0.09 (+0.15%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.49 /

-0.61 (-1.13%)

ABBV AbbVie
$99.34 /

+0.31 (+0.31%)

TEVA Teva
$11.22 /

-0.31 (-2.69%)

SNY Sanofi
$51.40 /

-0.78 (-1.49%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$34.03 /

-0.48 (-1.39%)

NVS Novartis
$87.77 /

-0.65 (-0.74%)

JNJ Johnson & Johnson
$142.81 /

-0.18 (-0.13%)

JAZZ Jazz Pharmaceuticals
$108.72 /

-2.48 (-2.23%)

IPSEY Ipsen
$0.00 /

+ (+0.00%)

GSK GlaxoSmithKline
$40.38 /

-0.625 (-1.52%)

BMY Bristol-Myers
$60.30 /

+0.09 (+0.15%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.49 /

-0.61 (-1.13%)

ABBV AbbVie
$99.34 /

+0.31 (+0.31%)

TEVA Teva
$11.22 /

-0.31 (-2.69%)

TAK Takeda Pharmaceutical
$17.48 /

-0.18 (-1.02%)

SNY Sanofi
$51.40 /

-0.78 (-1.49%)

PFE Pfizer
$34.03 /

-0.48 (-1.39%)

NVS Novartis
$87.77 /

-0.65 (-0.74%)

JNJ Johnson & Johnson
$142.81 /

-0.18 (-0.13%)

GSK GlaxoSmithKline
$40.38 /

-0.625 (-1.52%)

BMY Bristol-Myers
$60.30 /

+0.09 (+0.15%)

AZN AstraZeneca
$53.49 /

-0.61 (-1.13%)

ABBV AbbVie
$99.34 /

+0.31 (+0.31%)

Hot Stocks
Guardant Health, Jannssen seek approval of Guardant360 CDx with amivantamab » 08:15
07/08/20
07/08
08:15
07/08/20
08:15
GH

Guardant Health

$85.26 /

+0.03 (+0.04%)

, JNJ

Johnson & Johnson

$142.81 /

-0.18 (-0.13%)

Guardant Health (GH)…

Guardant Health (GH) announced a strategic collaboration with Janssen (JNJ) to pursue regulatory approval and commercialization of the Guardant360 CDx as a companion diagnostic for amivantamab, an investigational EGFR-MET bispecific antibody being studied in the treatment of non-small cell lung cancer, or NSCLC. The agreement covers the United States, Canada, Japan and Europe. The Guardant360 blood test is increasingly being used to guide treatment in metastatic cancer, as the number of treatment-relevant genomic alterations continues to grow. Using next-generation sequencing, the Guardant360 test analyzes 74 genes using cell-free tumor DNA from patient blood samples. The Guardant360 test is broadly covered by Medicare for use across the vast majority of advanced solid tumors, including patients with metastatic NSCLC.

ShowHide Related Items >><<
JNJ Johnson & Johnson
$142.81 /

-0.18 (-0.13%)

GH Guardant Health
$85.26 /

+0.03 (+0.04%)

GH Guardant Health
$85.26 /

+0.03 (+0.04%)

06/12/20
Fly Intel: Top five analyst initiations
06/12/20 BTIG
BTIG starts genomic profiling test 'pioneer' Guardant Health at Buy
06/11/20 BTIG
Guardant Health initiated with a Buy at BTIG
05/08/20 Citi
Guardant Health price target raised to $110 from $100 at Citi
JNJ Johnson & Johnson
$142.81 /

-0.18 (-0.13%)

07/06/20 Baird
Cooper Companies downgraded to Neutral, Baird see confluence of issues
07/01/20 JMP Securities
Minerva's seltorexant still 'underappreciated' upside driver, says JMP
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
05/29/20 H.C. Wainwright
H.C. Wainwright sees path forward for Minerva's roluperidone despite setback
JNJ Johnson & Johnson
$142.81 /

-0.18 (-0.13%)

GH Guardant Health
$85.26 /

+0.03 (+0.04%)

  • 02
    Jun
JNJ Johnson & Johnson
$142.81 /

-0.18 (-0.13%)

JNJ Johnson & Johnson
$142.81 /

-0.18 (-0.13%)

GH Guardant Health
$85.26 /

+0.03 (+0.04%)

JNJ Johnson & Johnson
$142.81 /

-0.18 (-0.13%)

Over a week ago
Hot Stocks
J&J cuts TB treatment bedaquiline price in low- and middle-income countries » 12:32
07/06/20
07/06
12:32
07/06/20
12:32
JNJ

Johnson & Johnson

$143.14 /

+2.13 (+1.51%)

The Stop TB Partnership…

The Stop TB Partnership and Johnson & Johnson - with support from the Global Fund to Fight AIDS, TB and Malaria, and the U.S. Agency for International Development -- announced joint efforts to help enable low- and middle-income countries to rapidly scale up use of SIRTURO, or bedaquiline, 100mg tablets in support of new, recently-released World Health Organization treatment guidelines. Effective immediately, Johnson & Johnson will make bedaquiline available to Stop TB Partnership's Global Drug Facility at a price of $340 per six-month treatment course for more than 135 eligible countries. To help support and accelerate further scale-up of all-oral treatment regimens, the company will also provide an escalating percentage of free goods when certain volume thresholds are reached on an annual basis: 10% above 55,000, 20% above 125,000 and 30% above 200,000 treatment courses. With support from the Global Fund and USAID, as well as governments and other partners, the Stop TB Partnership expects to receive confirmed orders for at least 125,000 people with DR-TB in 2020 and will, therefore, receive two treatments for free out of every 10 ordered. This would reduce the effective net price of bedaquiline by 32%, compared to the original $400 price. In the first year alone, this could lead to an estimated savings of up to USD$16M for national TB programs - equivalent to the amount needed to treat an additional 30,000 people with short-course DR-TB regimens. Reference Link

ShowHide Related Items >><<
JNJ Johnson & Johnson
$143.14 /

+2.13 (+1.51%)

JNJ Johnson & Johnson
$143.14 /

+2.13 (+1.51%)

07/06/20 Baird
Cooper Companies downgraded to Neutral, Baird see confluence of issues
07/01/20 JMP Securities
Minerva's seltorexant still 'underappreciated' upside driver, says JMP
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
05/29/20 H.C. Wainwright
H.C. Wainwright sees path forward for Minerva's roluperidone despite setback
JNJ Johnson & Johnson
$143.14 /

+2.13 (+1.51%)

JNJ Johnson & Johnson
$143.14 /

+2.13 (+1.51%)

JNJ Johnson & Johnson
$143.14 /

+2.13 (+1.51%)

JNJ Johnson & Johnson
$143.14 /

+2.13 (+1.51%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.